NeuroPace (NPCE) Projected to Post Quarterly Earnings on Tuesday

NeuroPace (NASDAQ:NPCE) is expected to be issuing its Q3 2025 results after the market closes on Tuesday, November 4th. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $24.6350 million for the quarter. NeuroPace has set its FY 2025 guidance at EPS.Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 4:30 PM ET.

NeuroPace (NASDAQ:NPCE) last posted its earnings results on Tuesday, August 12th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.02). NeuroPace had a negative net margin of 29.29% and a negative return on equity of 168.61%. The business had revenue of $23.52 million for the quarter, compared to analyst estimates of $23.08 million. On average, analysts expect NeuroPace to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NeuroPace Price Performance

NASDAQ:NPCE opened at $9.70 on Monday. NeuroPace has a 52 week low of $6.03 and a 52 week high of $18.98. The company has a quick ratio of 4.51, a current ratio of 5.47 and a debt-to-equity ratio of 3.02. The stock has a market capitalization of $320.71 million, a PE ratio of -11.70 and a beta of 1.90. The stock’s 50-day moving average price is $10.11 and its 200-day moving average price is $10.85.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on NPCE shares. Zacks Research cut NeuroPace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NeuroPace in a report on Wednesday, October 8th. Finally, Wells Fargo & Company lowered their price objective on NeuroPace from $17.00 to $15.00 and set an “overweight” rating on the stock in a report on Wednesday, August 13th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $16.60.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its holdings in shares of NeuroPace by 44.6% during the 2nd quarter. Geode Capital Management LLC now owns 485,162 shares of the company’s stock worth $5,406,000 after purchasing an additional 149,595 shares during the last quarter. Qube Research & Technologies Ltd boosted its holdings in shares of NeuroPace by 74.7% during the 2nd quarter. Qube Research & Technologies Ltd now owns 112,637 shares of the company’s stock worth $1,255,000 after purchasing an additional 48,175 shares during the last quarter. Lazard Asset Management LLC boosted its holdings in shares of NeuroPace by 2,445.5% during the 2nd quarter. Lazard Asset Management LLC now owns 78,885 shares of the company’s stock worth $878,000 after purchasing an additional 75,786 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of NeuroPace by 59.1% during the 2nd quarter. Russell Investments Group Ltd. now owns 71,463 shares of the company’s stock valued at $796,000 after buying an additional 26,547 shares during the period. Finally, Jump Financial LLC raised its position in shares of NeuroPace by 223.6% during the 2nd quarter. Jump Financial LLC now owns 40,474 shares of the company’s stock valued at $451,000 after buying an additional 27,965 shares during the period. 78.83% of the stock is currently owned by institutional investors and hedge funds.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.